Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Debt: 2011-2022

Historic Total Debt for Ligand Pharmaceuticals (LGND) over the last 8 years, with Dec 2022 value amounting to $76.7 million.

  • Ligand Pharmaceuticals' Total Debt was N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A change from last year.
  • As of FY2022, Ligand Pharmaceuticals' Total Debt stood at $76.7 million, which was up 190.15% from $26.4 million recorded in FY2018.
  • Over the past 5 years, Ligand Pharmaceuticals' Total Debt peaked at $76.7 million during FY2022, and registered a low of $26.4 million during FY2018.
  • Over the past 1 years, Ligand Pharmaceuticals' median Total Debt value was $76.7 million (recorded in 2022), while the average stood at $76.7 million.
  • Data for Ligand Pharmaceuticals' Total Debt shows a maximum YoY tumbled of 88.23% (in 2018) over the last 5 years.
  • Ligand Pharmaceuticals' Total Debt (Yearly) stood at $26.4 million in 2018, then followed by $76.7 million in 2022.